Research Article

Serum YKL-40 levels are associated with type 2 diabetes mellitus in patients with obstructive sleep apnea syndrome

Published: August 03, 2015
Genet. Mol. Res. 14 (3) : 8919-8925 DOI: 10.4238/2015.August.3.15

Abstract

Patients with obstructive sleep apnea syndrome (OSAS) have an increased risk for type 2 diabetes mellitus (T2DM). It has been recently demonstrated that serum YKL-40 levels, also named as human cartilage glycoprotein 39, are elevated in T2DM patients. The aim of this study was to determine whether serum YKL-40 levels are associated with T2DM in patients with OSAS. This study consisted of 432 patients with OSAS (234 and 198 patients with and without T2DM, respectively). Serum YKL-40 levels were examined using the enzyme-linked immunosorbent assay method. OSAS patients with T2DM had significantly elevated serum YKL-40 levels compared to those without T2DM [205.02 (146.16-272.70) vs 135.72 (114.06-163.38)]. According to the multivariable logistic regression analysis, serum YKL-40 levels were an independent determinant of T2DM in patients with OSAS. Furthermore, based on the linear regression analysis, serum YKL-40 levels were positively associated with the body mass index, systolic blood pressure, serum triglyceride levels, homeostasis model assessment of insulin resistance, and levels of C-reactive protein, fasting plasma glucose, 2-h postprandial plasma glucose, and HbA1c in patients with OSAS. Elevated serum YKL-40 levels may serve as a new biomarker to predict T2DM in patients with OSAS.

Patients with obstructive sleep apnea syndrome (OSAS) have an increased risk for type 2 diabetes mellitus (T2DM). It has been recently demonstrated that serum YKL-40 levels, also named as human cartilage glycoprotein 39, are elevated in T2DM patients. The aim of this study was to determine whether serum YKL-40 levels are associated with T2DM in patients with OSAS. This study consisted of 432 patients with OSAS (234 and 198 patients with and without T2DM, respectively). Serum YKL-40 levels were examined using the enzyme-linked immunosorbent assay method. OSAS patients with T2DM had significantly elevated serum YKL-40 levels compared to those without T2DM [205.02 (146.16-272.70) vs 135.72 (114.06-163.38)]. According to the multivariable logistic regression analysis, serum YKL-40 levels were an independent determinant of T2DM in patients with OSAS. Furthermore, based on the linear regression analysis, serum YKL-40 levels were positively associated with the body mass index, systolic blood pressure, serum triglyceride levels, homeostasis model assessment of insulin resistance, and levels of C-reactive protein, fasting plasma glucose, 2-h postprandial plasma glucose, and HbA1c in patients with OSAS. Elevated serum YKL-40 levels may serve as a new biomarker to predict T2DM in patients with OSAS.

About the Authors